Renal failure in multiple myeloma: something new on the horizon.
Offidani M et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14548. [Epub ahead of print].

Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients.
Vázquez L et al. Rev Esp Quimioter. 2017 Feb 14. pii: vazquez14feb2017. [Epub ahead of print].

Myelosuppression-sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilising a tedizolid-based regimen: a case report.
Matin A et al. Int J Antimicrob Agents. 2017 Feb 8. pii: S0924-8579(17)30039-0. doi: 10.1016/j.ijantimicag.2016.11.032. [Epub ahead of print].

Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.
Lum EL et al. Am J Kidney Dis. 2017 Feb 9. pii: S0272-6386(17)30005-7. doi: 10.1053/j.ajkd.2016.11.024. [Epub ahead of print].

Multiple myeloma presenting with bilateral ankle pain (microangiopathy) and complicated by streptococcal meningitis and Pneumocystis carinii pneumonia.
Dunphy L et al. BMJ Case Rep. 2017 Feb 7;2017. pii: bcr2016217289. doi: 10.1136/bcr-2016-217289.

Fatal Rhabdomyolysis Caused by Morganella morganii in a Patient with Multiple Myeloma.
Imataki O et al. Intern Med. 2017;56(3):369-371. doi: 10.2169/internalmedicine.56.7252. Epub 2017 Feb 1.

Epibulbar Plasmacytoma Masquerading as Subconjunctival Hemorrhage in a Patient With Multiple Myeloma.
Bradley A et al. Cornea. 2017 Feb;36(2):249-251. doi: 10.1097/ICO.0000000000001071.

Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
Sethi TK et al. Curr Hematol Malig Rep. 2017 Feb 23. doi: 10.1007/s11899-017-0369-y. [Epub ahead of print].